Mukka Proteins has successfully allotted 2 crore convertible warrants to 15 non-promoter investors at an issue price of Rs 23.50, raising a total of Rs 47 crore. The company has received the mandatory 25% upfront payment. Investors should note that the conversion of these warrants into equity shares within the 18-month window will lead to potential earnings dilution.
Mukka Proteins Allots 2 Crore Warrants for Rs 47 Crore
Mukka Proteins Ltd has officially allotted 2,00,00,000 convertible warrants at Rs 23.50 per unit.
The issuance raises Rs 47,00,00,000 in total consideration, with 25% already received as an upfront payment.
Reader Takeaway: The capital infusion strengthens the balance sheet, though future warrant-to-equity conversion will dilute existing shareholder earnings per share.
What just happened
The Board of Directors, acting on shareholder approval from July 2026, has finalized the preferential allotment of 2 crore warrants to 15 non-promoter investors. This move completes the company's planned fundraising exercise. Investors such as Vishal Maniar, Hiren Hiralal Shiyal, and Multiplex Capital Limited are among the allottees.
Why this matters
This infusion of capital provides Mukka Proteins with immediate liquidity through the 25% upfront subscription. The remaining 75% will be collected as and when the warrant holders exercise their right to convert these instruments into fully paid-up equity shares.
Terms and Conditions
- Issue Price: Rs 23.50 per warrant.
- Conversion Window: Within 18 months from the date of allotment.
- Security: Each warrant is convertible into one equity share of Re 1 face value.
- Forfeiture: If the conversion option is not exercised within 18 months, the warrants lapse and the 25% upfront payment is forfeited by the company.
Risks to watch
The primary concern for existing shareholders is the future equity dilution. Once these warrants are converted, the total number of outstanding shares will increase, which may exert downward pressure on earnings per share (EPS) metrics. Furthermore, all shares issued under this scheme are subject to lock-in requirements as mandated by SEBI ICDR regulations, limiting immediate liquidity for the allottees.
What to track next
Watch for the company's utilization of the funds raised and monitor any future announcements regarding the conversion of these warrants, as the 18-month window dictates the timing of equity expansion.